ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
BeiGene Ltd

BeiGene Ltd (BGNE)

152.735
-0.905
( -0.59% )
Updated: 12:26:53

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
152.735
Bid
152.51
Ask
152.95
Volume
75,523
148.81 Day's Range 155.01
0.00 52 Week Range 0.00
Market Cap
Previous Close
153.64
Open
150.74
Last Trade
49
@
152.72
Last Trade Time
12:27:28
Financial Volume
$ 11,570,848
VWAP
153.2096
Average Volume (3m)
-
Shares Outstanding
104,578,798
Dividend Yield
-
PE Ratio
-1.49
Earnings Per Share (EPS)
-8.43
Revenue
2.46B
Net Profit
-881.71M

About BeiGene Ltd

BeiGene Ltd is a commercial-stage biotechnology company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system ... BeiGene Ltd is a commercial-stage biotechnology company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1. Its geographical segments are China, the United States, and the Rest of the world. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Grand Cayman, Cym
Founded
1970
BeiGene Ltd is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker BGNE. The last closing price for BeiGene was $153.64. Over the last year, BeiGene shares have traded in a share price range of $ 0.00 to $ 0.00.

BeiGene currently has 104,578,798 shares outstanding. The market capitalization of BeiGene is $16.07 billion. BeiGene has a price to earnings ratio (PE ratio) of -1.49.

BGNE Latest News

ベイジーン、アーロン・ローゼンバーグ氏を最高財務責任者に任命

(ビジネスワイヤ) -- グローバル・オンコロジー企業のベイジーン(NASDAQ:BGNE;HKEX:06160;SSE:688235)は、アーロン・ローゼンバーグ氏を7月22日付で最高財務責任者(CFO)に任命したことを発表しまし...

BeiGene annonce la nomination d'Aaron Rosenberg au poste de Chief Financial Officer

BeiGene, Ltd. (NASDAQ : BGNE ; HKEX : 06160 ; SSE : 688235), société internationale d'oncologie, a annoncé aujourd'hui la nomination d'Aaron Rosenberg au poste de COO, à compter du 22 juillet. M...

BeiGene gibt die Ernennung von Aaron Rosenberg zum Finanzvorstand bekannt

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), ein globales Onkologieunternehmen, gab heute die Ernennung von Aaron Rosenberg zum Finanzvorstand mit Wirkung vom 22. Juli bekannt. Aaron...

BeiGene Announces Appointment of Aaron Rosenberg as Chief Financial Officer

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the appointment of Aaron Rosenberg as Chief Financial Officer, effective July 22. Mr. Rosenberg...

BeiGene présentera à l’EHA2024 de nouvelles données sur l’étude SEQUOIA évaluant la bithérapie BRUKINSA® plus vénétoclax dans le traitement de première intention de patients atteints de LLC/PLL à haut risque

Le groupe D de l’étude SEQUOIA a évalué des patients naïfs de traitement atteints de leucémie lymphoïde chronique ou de petit lymphome lymphocytaire avec del(17p) à haut risque et/ou avec...

EHA2024: BeiGene präsentiert neue Daten der SEQUOIA-Studie zu BRUKINSA® plus Venetoclax für die Erstlinienbehandlung von Hochrisiko-CLL/SLL

In Arm D der SEQUOIA-Studie wurden unbehandelte Hochrisikopatienten mit chronischer lymphozytischer Leukämie oder kleinzelligem lymphozytischem Lymphom und del(17p) und/oder TP53-Mutation...

BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA® plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024

Arm D of SEQUOIA study evaluated treatment-naïve patients with high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma with del(17p) and/or TP53 mutation Preliminary data suggest...

BeiGene and NewBridge Pharmaceuticals FZ LLC Mutually Agree to Conclude BRUKINSA® (Zanubrutinib) Partnership in the Middle East and Africa (MENA) Region

BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, and NewBridge Pharmaceuticals have jointly decided to conclude their partnership. This strategic decision aligns with...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000DR
40000000DR
120000000DR
260000000DR
520000000DR
1560000000DR
2600000000DR

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AGIXKraneShares Artificial Intelligence ETF
 24.66
(35,128.57%)
39.64k
ONCOOnconetix Inc
$ 0.2492
(67.25%)
359.28M
SILOSilo Pharma Inc
$ 3.4392
(52.85%)
85.79M
CHUYChuy s Holdings Inc
$ 37.395
(47.98%)
2.28M
SLRXSalarius Pharmaceuticals Inc
$ 2.25
(47.06%)
13.94M
AGENAgenus Inc
$ 7.92
(-55.33%)
6.63M
LESLLeslies Inc
$ 2.585
(-36.64%)
16.76M
SHOTWSafety Shot Inc
$ 0.26
(-36.59%)
1.56k
TCRTAlaunos Therapeutics Inc
$ 4.168
(-32.76%)
143.04k
CETUCetus Capital Acquisition Corporation
$ 7.35
(-25.83%)
139.64k
ONCOOnconetix Inc
$ 0.2492
(67.25%)
359.28M
NVDANVIDIA Corporation
$ 119.02
(0.87%)
186.01M
MAXNMaxeon Solar Technologies Ltd
$ 0.2373
(-2.79%)
128.88M
SQQQProShares UltraPro Short QQQ
$ 8.3386
(2.82%)
116.33M
SILOSilo Pharma Inc
$ 3.4392
(52.85%)
85.79M

BGNE Discussion

View Posts
MiamiGent MiamiGent 1 year ago
BGNE having a nice bounce and a good, steady day
9:40 AM +5.31%
10:45 AM +5.51%
3:18 PM +6.46%
https://stockcharts.com/h-sc/ui?s=BGNE
👍️0
MiamiGent MiamiGent 1 year ago
BGNE $271.915 +$6.91 (+2.609%)
Bid x Size
$271.06 x 1 Ask x Size $272.91 x 3
Volume 48,899

https://stockcharts.com/h-sc/ui?s=BGNE

BeiGene Says Brukinsa Gets UK Marketing Authorization for Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma
MT NEWSWIRES

08:38 AM EST, 01/19/2023 (MT Newswires) -- BeiGene (BGNE) said Thursday that the UK Medicines and Healthcare products Regulatory Agency has granted marketing authorizations for Brukinsa for the treatment of both chronic lymphocytic leukemia and marginal zone lymphoma.
(con't)
👍️0
MiamiGent MiamiGent 2 years ago
BGNE presently $269.42 +$6.19 (+2.35%)

Little drop from its ascent

Just took a position

https://stockcharts.com/h-sc/ui?s=BGNE
👍️0
luke424 luke424 2 years ago
Looking good!
👍️0
luke424 luke424 2 years ago
Last year, I think Bernstein had price target of $431. If SEC and China reach full agreement, the possibility is there. IP
👍️0
luke424 luke424 2 years ago
Great, Old timers will soon begin loading up China stocks!
https://www.bloomberg.com/news/articles/2022-04-01/china-weighs-giving-u-s-full-access-to-audits-of-most-firms?srnd=markets-vp
👍️0
luke424 luke424 2 years ago
Made a nice bet. Bought yesterday. https://www.cnbc.com/2022/04/01/china-securities-regulator-on-us-listed-chinese-stocks-audit-delisting.html
👍️0
north40000 north40000 5 years ago
AMGN to acquire 20% stake in BGNE; joint development of oncology assets in China.
👍️0
StockLearner2011 StockLearner2011 5 years ago
Market sentiment is not good for pharmaceutical company, but BGNE is still a bargain. Just bought 1000 shares waiting for rebound
👍️0
StockLearner2011 StockLearner2011 5 years ago
Hope no one will jump down the window if buyout happens ??
👍️0
StockLearner2011 StockLearner2011 5 years ago
Buy out is not going to happen that soon, but the stock price will make a big strike towards $200 soon enough
👍️0
StockLearner2011 StockLearner2011 5 years ago
Looking at insider transactions, the total shares bought by insiders over the course of 12 months is a lot more than they sold. The stock has great upward movement potential
👍️0
StockLearner2011 StockLearner2011 6 years ago
Howard Liang could have made 40000 X $22 = $880000 more if he held the shares for 2 more days to sell them
https://www.gurufocus.com/news/648598/beigene-ltd-bgne-ceo-john-oyler-sold-144-million-of-shares
👍️0
StockLearner2011 StockLearner2011 6 years ago
https://www.gurufocus.com/news/648598/beigene-ltd-bgne-ceo-john-oyler-sold-144-million-of-shares
👍️0
StockLearner2011 StockLearner2011 6 years ago
https://www.gurufocus.com/news/648598/beigene-ltd-bgne-ceo-john-oyler-sold-144-million-of-shares
👍️0
StockLearner2011 StockLearner2011 6 years ago
https://stocknewstimes.com/2018/03/21/beigene-ltd-bgne-cfo-howard-liang-sells-10872-shares.html
👍️0
StockLearner2011 StockLearner2011 6 years ago
https://finviz.com/quote.ashx?t=Bgne
The chart looks traight shooting up!
👍️0
StockLearner2011 StockLearner2011 6 years ago
Strong buy!
👍️0
StockLearner2011 StockLearner2011 6 years ago
Hot stock. It's looking strong!
👍️0
SweepsMcGee SweepsMcGee 6 years ago
BeiGene Announces Approval of REVLIMID® for Newly Diagnosed Multiple Myeloma in China

BEIJING, China, and CAMBRIDGE, Mass., Feb. 27, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, today announced that REVLIMID® (lenalidomide) has been approved by the China Food and Drug Administration (CFDA) for the treatment of multiple myeloma (MM) in combination with dexamethasone in adult patients with previously untreated MM who are not eligible for transplant. REVLIMID is an oral immunomodulatory drug that was first approved by the CFDA in China in 2013 for the treatment of MM in combination with dexamethasone, in adult patients who have received at least one prior therapy. It is currently marketed in China by BeiGene under an exclusive license from Celgene Corporation.

“REVLIMID is an important part of our commercial and development plans in China, where we are expanding our portfolio and commercial footprint. In China, where the incidence of multiple myeloma is on the rise due to an aging population and improved diagnosis, we are hopeful that newly diagnosed patients will have a meaningful long-term benefit from this approval,” commented John V. Oyler, Founder, Chief Executive Officer, and Chairman of BeiGene.

In a large randomized, three-arm, open-label Phase 3 trial (CC-5013-MM-020) conducted to compare the efficacy and safety of REVLIMID and low dose dexamethasone (Rd) to that of melphalan, prednisone and thalidomide (MPT) in patients with newly diagnosed multiple myeloma (NDMM) who were not eligible for transplant, continuous REVLIMID plus dexamethasone (Rd continuous) significantly improved median progression-free survival (PFS) compared to the MPT arm with a hazard ratio (HR) of 0.72 (95% Confidence Interval (CI): 0.61-0.85, p <0.0001) and a median PFS of 25.5 vs. 21.2 months. The median overall survival was 10.4 months longer with Rd continuous vs. MPT (58.9 vs. 48.5 months, HR of 0.75 (95% CI: 0.62-0.90)). Similarly, the response rate was also higher with Rd continuous compared with MPT (75.1% vs. 62.3%); with a complete response in 15.1% of Rd continuous arm patients vs. 9.3% in the MPT arm.

The most common grade 3/4 adverse events (occurring in ≥ 10% of patients in any subgroup) in the Rd continuous arm, Rd for 72 weeks (18 cycles; Rd18 arm) or MPT arm in the trial included neutropenia (28%, 27%, 45%, respectively), anemia (18%, 16%, 19%), thrombocytopenia (8%, 8%,11%) and pneumonia (11%, 11%, 8%).

About Multiple Myeloma

Multiple myeloma is an incurable and life-threatening blood cancer that is characterized by tumor proliferation and suppression of the immune system.i It can appear as both a tumor and/or an area of bone loss, and it affects the places where bone marrow is active in an adult: the hollow area within the bones of the spine, skull, pelvis, rib cage, and the areas around the shoulders and hips.ii MM is the second most commonly diagnosed blood cancer. According to the International Myeloma Foundation, there are an estimated 750,000 MM patients worldwide.iii

About REVLIMID

In China, REVLIMID is now approved in combination with dexamethasone for the treatment of adult NDMM patients who are not eligible for transplant. It received approval in China in 2013 for the treatment of MM in combination with dexamethasone, in adult patients who have received at least one prior therapy.

REVLIMID, in combination with dexamethasone, is approved in the United States, in Europe, in Japan and in around 25 other countries for the treatment of adult patients with previously untreated MM who are not eligible for transplant. REVLIMID is also approved in combination with dexamethasone for the treatment of MM patients who have received at least one prior therapy in nearly 70 countries, encompassing Europe, the Americas, the Middle East and Asia, and in combination with dexamethasone for the treatment of patients whose disease has progressed after one therapy in Australia and New Zealand.

REVLIMID is also approved in the United States, Canada, Switzerland, Australia, New Zealand and several Latin American countries, as well as Malaysia and Israel, for transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities and in Europe for the treatment of patients with transfusion-dependent anemia due to low- or intermediate-1-risk MDS associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.

In addition, REVLIMID is approved in the United States and Europe for the treatment of patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib. In Switzerland, REVLIMID is indicated for the treatment of patients with relapsed or refractory MCL after prior therapy that included bortezomib and chemotherapy/rituximab.

REVLIMID is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials.
👍️0
north40000 north40000 6 years ago
BGNE: New message board for a Chinese biotech company. CEO has Ph. D. from Texas-based UTSW. The company has recently raised substantial funds, and is focused on immuno-therapy market. Its share price has risen faster in past 6 months than others on my watch list.
👍️0

Your Recent History

Delayed Upgrade Clock